Answers are grounded in this paper and cite their sources.
Over the past decade, the treatment landscape for inflammatory bowel disease (IBD) has evolved significantly, driven by the introduction of new biologic and advanced small molecule therapies. While these therapies have been rigorously studied and approved in adults, a major gap remains in pediatric-specific data on their positioning, dosing, safety, and effectiveness. Pediatric patients often have unique considerations regarding treatment,1,2 underscoring the need for dedicated pediatric research. Despite the growing range of therapeutic options, clinicians still lack tools to predict which patients will respond to specific therapies. Furthermore, approximately 15% of children with Crohn’s disease (CD) undergo surgery within five years of diagnosis,3 yet data on optimal surgical candidates, post-operative outcomes, and best practices for post-surgical management remain limited. To address these gaps, we sought to develop a large multi-center translational, prospective pediatric IBD cohort aimed at transforming our understanding and treatment of pediatric IBD. Previous landmark IBD studies—RISK stratification study for pediatric CD4 and predicting response to standardized pediatric colitis therapy (PROTECT) for pediatric ulcerative colitis (UC)5—have substantially advanced the field of pediatric IBD. RISK demonstrated the superiority of early infliximab therapy in pediatric CD and identified early predictors of complicated disease course; while PROTECT identified key factors associated with clinical remission in pediatric UC following standardized treatment with mesalamine and initial corticosteroids.
No takes yet. Share an insight, caveat, or question.
Subedi et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: